European Patent Office Revokes Merck's Fosamax Patent
In a setback for U.S. drug maker Merck, the European Patent Office has revoked the European patent for Fosamax Once Weekly, Merck's hormone treatment for osteoporosis and other bone-weakening diseases....To view the full article, register now.
Already a subscriber? Click here to view full article